Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Study details include:
The study duration will be up to 63 days (9 weeks).
Number of Participants:
The study will randomise approximately 36 participants in total. Cohort A: Approximately 75 participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. Cohort B: Approximately 75 participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort A | Other | Participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. |
|
| Cohort B | Other | Participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD2389 | Drug | Doses of AZD2389 or placebo will be administered orally. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis) | The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria. | From screening up to and including Day 35 |
| Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG) | The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities. | From Screening up to and including Day 35 |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax |
Not provided
Key inclusions:
Key exclusions:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Chandler | Arizona | 85224 | United States | ||
| Research Site |
Not provided
| Label | URL |
|---|---|
| d7930c00002\_Redacted CSR synopsis | View source |
| d7930c00002\_Redacted\_SAP | View source |
Not provided
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Of the 95 participants, 40 were eligible for the study: 22 with presumed MASH/NASH with fibrosis (Cohort A) and 18 with underlying SLDs of varying aetiologies (Cohort B).
A total of 95 participants were screened for the study at 9 centres (1 in the UK and 8 in the US).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cohort A - AZD2389 | Participants with presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)/Nonalcoholic Steatohepatitis (NASH) with fibrosis who received AZD2389. |
| FG001 | Cohort A - Placebo |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Apr 17, 2025 | May 5, 2026 |
Not provided
Not provided
The total duration of study participation for each participant in Cohorts A and B will be approximately 63 days (9 weeks) and will include an up to 28-day screening period, a 28-day treatment period, and a follow-up visit seven days following completion of treatment.
Assessments will be conducted as described in the SoA.
Not provided
Not provided
This is a single-blind, randomized, placebo-controlled study with up to 2 study intervention cohorts that are participant and investigator-blinded.
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration |
| Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28. | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve | Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax | Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24) | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine | Day 1 and Day 28 |
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24) | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine | Day 1 and Day 28 |
| Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo. | Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) *100. FAP=Fibroblast Activating Protein | Day 28 |
| Rialto |
| California |
| 92377 |
| United States |
| Research Site | Atlanta | Georgia | 30349 | United States |
| Research Site | Morehead City | North Carolina | 28557 | United States |
| Research Site | Houston | Texas | 77079 | United States |
| Research Site | San Antonio | Texas | 78215 | United States |
| Research Site | San Antonio | Texas | 78229 | United States |
| Research Site | San Juan | 00927 | Puerto Rico |
| Research Site | Cambridge | CB2 0QQ | United Kingdom |
| d7930c00002\_Redacted\_CSP | View source |
Participants with presumed MASH/NASH with fibrosis who received placebo.
| FG002 | Cohort B - AZD2389 | Participants with underlying Steatotic Liver Diseases (SLDs) of varying aetiologies and advanced fibrosis including compensated cirrhosis who received AZD2389. |
| FG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cohort A - AZD2389 | Participants with presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)/Nonalcoholic Steatohepatitis (NASH) with fibrosis who received AZD2389. |
| BG001 | Cohort A - Placebo | Participants with presumed MASH/NASH with fibrosis who received placebo. |
| BG002 | Cohort B - AZD2389 | Participants with underlying Steatotic Liver Diseases (SLDs) of varying aetiologies and advanced fibrosis including compensated cirrhosis who received AZD2389. |
| BG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Age at screening | Mean | Standard Deviation | years |
| ||||||||||||||
| Age, Customized | Age at Screening | Full Analysis Set | Number | Participants |
| ||||||||||||||
| Sex: Female, Male | Full Analysis Set | Count of Participants | Participants |
| |||||||||||||||
| Race/Ethnicity, Customized | Full Analysis Set | Number | Participants |
| |||||||||||||||
| Race/Ethnicity, Customized | Full Analysis Set | Number | Participants |
| |||||||||||||||
| Region of Enrollment | Full Analysis Set | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | nmol/L | Day 1 and Day 28 |
|
|
| |||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Median | Full Range | hour | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | hour | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28. | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | h*nmol/L | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | 1/h | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | L | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | L/h | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24) | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | mg | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24) | The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine | PK analysis set: This included all participants who received AZD2389 and had at least one evaluable PK concentration | Posted | Geometric Mean | Geometric Coefficient of Variation | % of fraction of dose unchanged | Day 1 and Day 28 |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis) | The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria. | Safety analysis set. All participants who were randomised and received at least one dose of study intervention were analysed. | Posted | Count of Participants | Participants | From screening up to and including Day 35 |
| ||||||||||||||||||||||||||||||||||||||||||||
| Primary | Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG) | The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities. | Safety analysis set. All participants who were randomised and received at least one dose of study intervention were analysed. | Posted | Count of Participants | Participants | From Screening up to and including Day 35 |
| ||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo. | Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) *100. FAP=Fibroblast Activating Protein | Full analysis set: The Full Analysis Set consisted of all participants who were randomised and received at least at least one dose of study intervention | Posted | Geometric Least Squares Mean | 95% Confidence Interval | % of change in FAP activity | Day 28 |
|
From screening to Day 35 up to 63 days
Includes adverse events with an onset date on or after the date of first dose of investigational product (IP) up to and including 7 days following the date of last IP dose.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cohort A - AZD2389 | Participants with presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)/Nonalcoholic Steatohepatitis (NASH) with fibrosis who received AZD2389. | 0 | 14 | 0 | 14 | 6 | 14 |
| EG001 | Cohort A - Placebo | Participants with presumed MASH/NASH with fibrosis who received placebo. | 0 | 8 | 0 | 8 | 3 | 8 |
| EG002 | Cohort B - AZD2389 | Participants with underlying Steatotic Liver Diseases (SLDs) of varying aetiologies and advanced fibrosis including compensated cirrhosis who received AZD2389. | 0 | 12 | 0 | 12 | 1 | 12 |
| EG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. | 0 | 6 | 0 | 6 | 1 | 6 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Blood creatine phosphokinase increased | Investigations | MedDRA 28.0 | Systematic Assessment |
| |
| Electrocardiogram qt prolonged | Investigations | MedDRA 28.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Dysuria | Renal and urinary disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Gastroenteritis viral | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Rhinitis | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 28.0 | Systematic Assessment |
|
The investigator shall be entitled to publish the results of, or make presentations related to, the study provided that any publications or presentations to be made within 2 years after completion of the study shall require the sponsor's prior written consent.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Clinical Lead | AstraZeneca | 1-877-240-9479 | information.center@astrazeneca.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 10, 2025 | May 5, 2026 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D008103 | Liver Cirrhosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| >= 65 |
|
| Male |
|
| Not Hispanic or Latino |
|
| Asian |
|
| Black or African American |
|
| Native Hawaiian or other Pacific Islander |
|
| Not reported |
|
| Other |
|
| White |
|
|
|
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo.
|
|
| OG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
|
|
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo.
|
|
|
|
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo.
|
|
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
|
|
| Cohort B - Placebo |
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
|
|
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo.
|
|
Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo.
|
|
| OG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
|
|
| OG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
|
|
| OG003 | Cohort B - Placebo | Participants with underlying SLDs of varying aetiologies and advanced fibrosis including compensated cirrhosis who received placebo. |
|
|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|